R&D channel feed – Endpoints News

R&D channel feed

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

8 years ago

PD-L1 checkpoint player Merck KGaA dives into next-gen work with F-star collaboration

8 years ago

AstraZeneca’s PARP drug Lynparza easily outscores chemo in PhIII breast cancer study

8 years ago

J&J’s stellar prostate cancer data signals the likelihood of a broader market approval, as Pfizer rival struggles

8 years ago

Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat

8 years ago

Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval

8 years ago

Endocyte slashes staff and retrenches in the wake of back-to-back R&D setbacks

8 years ago

Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII

8 years ago

Alexion’s new CEO is bringing an old colleague in to run R&D, can new deals be far behind?

8 years ago

Checkpoint combos for cancer are all the rage as trial sponsors line up hundreds of new studies — report

9 years ago

ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead

9 years ago

New report heralds a revolution in cancer R&D trends - and the sticker shock that comes with it

9 years ago

Teva's CGRP migraine drug aces PhIII while rivals pile up at the FDA finish line

9 years ago

Scripps researchers add power to antibiotic vancomycin, giving it a third mechanism to fight superbugs

9 years ago

Alnylam preps for another PhIII RNAi study, ‘breakthrough’ status in hand

9 years ago

Akari CEO abruptly resigns as a special committee moves a PhII patient success into the fail column

9 years ago

Another old, cheap generic is being prepped for an FDA application — made over into a ‘new’ drug for ADHD and narcolepsy

9 years ago

Novartis isn’t messing around with CAR-T, and it has a promising next-gen therapy to help prove it

9 years ago

Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential

9 years ago

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

9 years ago

Kite catches the inside track on the last leg of a race to the finish line with Novartis on a CAR-T first

9 years ago

BioCryst gets a big boost from its latest HAE data, but it still faces a dangerous high wire act and giant rivals

9 years ago

GW Pharma details an impressive PhIII case for a cannabis-based drug for severe epilepsy as it preps an NDA

9 years ago

Aerie shares shoot up as investigators take another big step to an NDA with 2nd positive glaucoma PhIII

9 years ago

First page Previous page 298 299 300301302 303 304 Next page Last page